Header Logo
Keywords
Last Name
Institution
Announcement

You can now add alternative names! Click here to add other names that you've published under.
 Back to Details

Connection

Mayumi Nakagawa to Humans

This is a "connection" page, showing publications Mayumi Nakagawa has written about Humans.

 
Connection Strength
  
 
 
0.579
  
  1. Shibata T, Shah S, Evans T, Coleman H, Lieblong BJ, Spencer HJ, Quick CM, Sasagawa T, Stephens OW, Peterson E, Johann D, Lu YC, Nakagawa M. Expansion of Human Papillomavirus-Specific T Cells in Periphery and Cervix in a Therapeutic Vaccine Recipient Whose Cervical High-Grade Squamous Intraepithelial Lesion Regressed. Front Immunol. 2021; 12:645299.
    View in: PubMed
    Score: 0.033
  2. Shah SK, Jones-Carr M, Bimali M, Su LJ, Nakagawa M. An Online Survey and Focus Groups for Promoting Cancer Prevention Measures. J Cancer Educ. 2022 12; 37(6):1782-1789.
    View in: PubMed
    Score: 0.032
  3. Shah SK, Demmings BE, Bimali M, Hadden K, Nakagawa M. Assessing the Feasibility of an Online Module for Promoting Cancer Prevention Measures. Cancer Control. 2021 Jan-Dec; 28:10732748211037908.
    View in: PubMed
    Score: 0.031
  4. Shibata T, Lieblong BJ, Sasagawa T, Nakagawa M. The promise of combining cancer vaccine and checkpoint blockade for treating HPV-related cancer. Cancer Treat Rev. 2019 Aug; 78:8-16.
    View in: PubMed
    Score: 0.028
  5. Ravilla R, Coleman HN, Chow CE, Chan L, Fuhrman BJ, Greenfield WW, Robeson MS, Iverson K, Spencer H, Nakagawa M. Cervical Microbiome and Response to a Human Papillomavirus Therapeutic Vaccine for Treating High-Grade Cervical Squamous Intraepithelial Lesion. Integr Cancer Ther. 2019 Jan-Dec; 18:1534735419893063.
    View in: PubMed
    Score: 0.027
  6. Coleman HN, Greenfield WW, Stratton SL, Vaughn R, Kieber A, Moerman-Herzog AM, Spencer HJ, Hitt WC, Quick CM, Hutchins LF, Mackintosh SG, Edmondson RD, Erickson SW, Nakagawa M. Human papillomavirus type 16 viral load is decreased following a therapeutic vaccination. Cancer Immunol Immunother. 2016 May; 65(5):563-73.
    View in: PubMed
    Score: 0.022
  7. Moerman-Herzog A, Nakagawa M. Early Defensive Mechanisms against Human Papillomavirus Infection. Clin Vaccine Immunol. 2015 Aug; 22(8):850-7.
    View in: PubMed
    Score: 0.021
  8. Nakagawa M, Greenfield W, Moerman-Herzog A, Coleman HN. Cross-Reactivity, Epitope Spreading, and De Novo Immune Stimulation Are Possible Mechanisms of Cross-Protection of Nonvaccine Human Papillomavirus (HPV) Types in Recipients of HPV Therapeutic Vaccines. Clin Vaccine Immunol. 2015 Jul; 22(7):679-87.
    View in: PubMed
    Score: 0.021
  9. Stratton SL, Spencer HJ, Greenfield WW, Low G, Hitt WC, Quick CM, Jeffus SK, Blackmon V, Nakagawa M. A novel use of a statewide telecolposcopy network for recruitment of participants in a Phase I clinical trial of a human papillomavirus therapeutic vaccine. Clin Trials. 2015 Jun; 12(3):199-204.
    View in: PubMed
    Score: 0.020
  10. Nakagawa M, Coleman HN, Wang X, Daniels J, Sikes J, Nagarajan UM. IL-12 secretion by Langerhans cells stimulated with Candida skin test reagent is mediated by dectin-1 in some healthy individuals. Cytokine. 2014 Feb; 65(2):202-9.
    View in: PubMed
    Score: 0.019
  11. Wang X, Coleman HN, Nagarajan U, Spencer HJ, Nakagawa M. Candida skin test reagent as a novel adjuvant for a human papillomavirus peptide-based therapeutic vaccine. Vaccine. 2013 Dec 02; 31(49):5806-13.
    View in: PubMed
    Score: 0.019
  12. Nakagawa M, Spencer HJ, Coleman HN, Greenfield WW. Distribution of human papillomavirus (HPV) types and anti-HPV T-cell immune responses among different racial/ethnic groups in Central Arkansas. J Ark Med Soc. 2013 Jan; 109(8):160-3.
    View in: PubMed
    Score: 0.018
  13. Post GR, James L, Alapat D, Guillory V, Cottler-Fox M, Nakagawa M. A case of acquired dysfibrinogenemia in multiple myeloma treated with therapeutic plasma exchange. Transfus Apher Sci. 2013 Feb; 48(1):35-8.
    View in: PubMed
    Score: 0.017
  14. Wang X, Greenfield WW, Coleman HN, James LE, Nakagawa M. Use of interferon-? enzyme-linked immunospot assay to characterize novel T-cell epitopes of human papillomavirus. J Vis Exp. 2012 Mar 08; (61).
    View in: PubMed
    Score: 0.017
  15. Kim KH, Greenfield WW, Cannon MJ, Coleman HN, Spencer HJ, Nakagawa M. CD4+ T-cell response against human papillomavirus type 16 E6 protein is associated with a favorable clinical trend. Cancer Immunol Immunother. 2012 Jan; 61(1):63-70.
    View in: PubMed
    Score: 0.016
  16. Kim KH, Horn TD, Pharis J, Kincannon J, Jones R, O'Bryan K, Myers J, Nakagawa M. Phase 1 clinical trial of intralesional injection of Candida antigen for the treatment of warts. Arch Dermatol. 2010 Dec; 146(12):1431-3.
    View in: PubMed
    Score: 0.015
  17. Veeraputhiran M, Ware J, Dent J, Bornhorst J, Post G, Cottler-Fox M, Pesek G, Theus J, Nakagawa M. A comparison of washed and volume-reduced platelets with respect to platelet activation, aggregation, and plasma protein removal. Transfusion. 2011 May; 51(5):1030-6.
    View in: PubMed
    Score: 0.015
  18. Nakagawa M, Gupta SK, Coleman HN, Sellers MA, Banken JA, Greenfield WW. A favorable clinical trend is associated with CD8 T-cell immune responses to the human papillomavirus type 16 e6 antigens in women being studied for abnormal pap smear results. J Low Genit Tract Dis. 2010 Apr; 14(2):124-9.
    View in: PubMed
    Score: 0.015
  19. Wang X, Santin AD, Bellone S, Gupta S, Nakagawa M. A novel CD4 T-cell epitope described from one of the cervical cancer patients vaccinated with HPV 16 or 18 E7-pulsed dendritic cells. Cancer Immunol Immunother. 2009 Feb; 58(2):301-8.
    View in: PubMed
    Score: 0.013
  20. Wang X, Moscicki AB, Tsang L, Brockman A, Nakagawa M. Memory T cells specific for novel human papillomavirus type 16 (HPV16) E6 epitopes in women whose HPV16 infection has become undetectable. Clin Vaccine Immunol. 2008 Jun; 15(6):937-45.
    View in: PubMed
    Score: 0.013
  21. Kim KH, Greenfield W, Shotts E, Nakagawa M. Detection of human papillomavirus type 16-specific T lymphocytes by a recombinant vaccinia virus-based enzyme-linked immunospot assay. Clin Vaccine Immunol. 2007 Apr; 14(4):362-8.
    View in: PubMed
    Score: 0.012
  22. Nakagawa M, Kim KH, Gillam TM, Moscicki AB. HLA class I binding promiscuity of the CD8 T-cell epitopes of human papillomavirus type 16 E6 protein. J Virol. 2007 Feb; 81(3):1412-23.
    View in: PubMed
    Score: 0.012
  23. Kim KH, Dishongh R, Santin AD, Cannon MJ, Bellone S, Nakagawa M. Recognition of a cervical cancer derived tumor cell line by a human papillomavirus type 16 E6 52-61-specific CD8 T cell clone. Cancer Immun. 2006 Jun 30; 6:9.
    View in: PubMed
    Score: 0.011
  24. Nakagawa M, Kim KH, Moscicki AB. Patterns of CD8 T-cell epitopes within the human papillomavirus type 16 (HPV 16) E6 protein among young women whose HPV 16 infection has become undetectable. Clin Diagn Lab Immunol. 2005 Aug; 12(8):1003-5.
    View in: PubMed
    Score: 0.011
  25. Toy P, Hollis-Perry KM, Jun J, Nakagawa M. Recipients of blood from a donor with multiple HLA antibodies: a lookback study of transfusion-related acute lung injury. Transfusion. 2004 Dec; 44(12):1683-8.
    View in: PubMed
    Score: 0.010
  26. Nakagawa M, Toy P. Acute and transient decrease in neutrophil count in transfusion-related acute lung injury: cases at one hospital. Transfusion. 2004 Dec; 44(12):1689-94.
    View in: PubMed
    Score: 0.010
  27. Nakagawa M, Kim KH, Moscicki AB. Different methods of identifying new antigenic epitopes of human papillomavirus type 16 E6 and E7 proteins. Clin Diagn Lab Immunol. 2004 Sep; 11(5):889-96.
    View in: PubMed
    Score: 0.010
  28. Nakagawa M, Dempsey DA, Haller C, Toy P. Safe lead levels: blood transfusion of extremely low birth weight infants. Clin Pediatr (Phila). 2004 Sep; 43(7):681.
    View in: PubMed
    Score: 0.010
  29. Dai L, Wilson LG, Nakagawa M, Qin Z. Coinfections with additional oncoviruses in HPV+ individuals: Status, function and potential clinical implications. J Med Virol. 2024 Jan; 96(1):e29363.
    View in: PubMed
    Score: 0.010
  30. Nakagawa M, Viscidi R, Deshmukh I, Costa MD, Palefsky JM, Farhat S, Moscicki AB. Time course of humoral and cell-mediated immune responses to human papillomavirus type 16 in infected women. Clin Diagn Lab Immunol. 2002 Jul; 9(4):877-82.
    View in: PubMed
    Score: 0.009
  31. Shibata T, Nakagawa M, Coleman HN, Owens SM, Greenfield WW, Sasagawa T, Robeson MS. Evaluation of DNA extraction protocols from liquid-based cytology specimens for studying cervical microbiota. PLoS One. 2021; 16(8):e0237556.
    View in: PubMed
    Score: 0.008
  32. Matsumoto T, Oda Y, Hasegawa Y, Hashimura M, Oguri Y, Inoue H, Yokoi A, Tochimoto M, Nakagawa M, Jiang Z, Saegusa M. Anaplastic Lymphoma Kinase Overexpression Is Associated with Aggressive Phenotypic Characteristics of Ovarian High-Grade Serous Carcinoma. Am J Pathol. 2021 10; 191(10):1837-1850.
    View in: PubMed
    Score: 0.008
  33. Matsumoto T, Chino H, Akiya M, Hashimura M, Yokoi A, Tochimoto M, Nakagawa M, Jiang Z, Saegusa M. Requirements of LEFTY and Nodal overexpression for tumor cell survival under hypoxia in glioblastoma. Mol Carcinog. 2020 12; 59(12):1409-1419.
    View in: PubMed
    Score: 0.008
  34. Shah SK, Nakagawa M, Lieblong BJ. Examining aspects of successful community-based programs promoting cancer screening uptake to reduce cancer health disparity: A systematic review. Prev Med. 2020 12; 141:106242.
    View in: PubMed
    Score: 0.008
  35. Wongsurawat T, Nakagawa M, Atiq O, Coleman HN, Jenjaroenpun P, Allred JI, Trammel A, Puengrang P, Ussery DW, Nookaew I. An assessment of Oxford Nanopore sequencing for human gut metagenome profiling: A pilot study of head and neck cancer patients. J Microbiol Methods. 2019 11; 166:105739.
    View in: PubMed
    Score: 0.007
  36. Kamiya T, Hira D, Hoshino N, Kurihara M, Nakagawa M, Sasaki M, Terada T. Low Body Mass Index and Myeloablative Conditioning Regimen Prolong the Duration of Parenteral Nutrition During Hematopoietic Stem Cell Transplantation. Ann Nutr Metab. 2019; 74(2):107-114.
    View in: PubMed
    Score: 0.007
  37. Wang X, Che Y, Chen B, Zhang Y, Nakagawa M, Wang X. Evaluation of immune responses induced by a novel human papillomavirus type 16 E7 peptide-based vaccine with Candida skin test reagent as an adjuvant in C57BL/6 mice. Int Immunopharmacol. 2018 Mar; 56:249-260.
    View in: PubMed
    Score: 0.006
  38. Pandey S, Nakagawa M, Rosenbaum ER, Arnaoutakis K, Hutchins LF, Makhoul I, Milojkovic N, Cottler-Fox M. Rituximab and intermediate-purity plasma-derived factor VIII concentrate (Koate?) as adjuncts to therapeutic plasma exchange for thrombotic thrombocytopenic purpura in patients with an ADAMTS13 inhibitor. J Clin Apher. 2015 Feb; 30(1):50-4.
    View in: PubMed
    Score: 0.005
  39. Farhat S, Nakagawa M, Moscicki AB. Cell-mediated immune responses to human papillomavirus 16 E6 and E7 antigens as measured by interferon gamma enzyme-linked immunospot in women with cleared or persistent human papillomavirus infection. Int J Gynecol Cancer. 2009 May; 19(4):508-12.
    View in: PubMed
    Score: 0.003
  40. Tugizov S, Berline J, Herrera R, Penaranda ME, Nakagawa M, Palefsky J. Inhibition of human papillomavirus type 16 E7 phosphorylation by the S100 MRP-8/14 protein complex. J Virol. 2005 Jan; 79(2):1099-112.
    View in: PubMed
    Score: 0.003
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.